• Explore /
  • Poster
  • / KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.

KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.

Abstract Poster

Authors

Georgina Long

Georgina V. Long

The University of Sydney, Sydney, NSW, Australia

Georgina V. Long , Alexander M. Eggermont , Jeffrey E. Gershenwald , Dirk Schadendorf , Paolo Antonio Ascierto , Reinhard Dummer , Axel Hauschild , Matteo S. Carlino , Antoni Ribas , Caroline Robert , Richard A. Scolyer , Vernon K. Sondak , Jonathan E Cohen , Jinchun Zhang , Dmitri O. Grebennik , Clemens Krepler , Jason J. Luke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT05665595

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS9611)

DOI

10.1200/JCO.2023.41.16_suppl.TPS9611

Abstract #

TPS9611

Poster Bd #

364b

Abstract Disclosures

Similar Posters

First Author: Neal D. Shore

First Author: Peter C.C. Fong

First Author: Girish S. Kulkarni

First Author: Mason Webb